# Association between estimated glucose disposal rate and major adverse cardiovascular events in patients with type 2 diabetes

## TL;DR

Lower glucose disposal rates in type 2 diabetes patients are linked to higher risks of heart problems and death, partly due to unstable blood sugar levels.

## Contribution

This study reveals that estimated glucose disposal rate (eGDR) is a significant predictor of cardiovascular risks in type 2 diabetes patients, mediated by HbA1c variability.

## Key findings

- Lower eGDR is associated with increased major adverse cardiovascular events and mortality.
- HbA1c variability mediates about 37.8% of the eGDR effect on cardiovascular risks.
- The relationship between eGDR and outcomes follows a nonlinear pattern, flattening after a threshold.

## Abstract

Estimated glucose disposal rate (eGDR) is associated with risk of adverse outcomes in patients with type 2 diabetes. However, whether eGDR affects long-term glycemic management in patients with type 2 diabetes remains unclear. This study aimed to investigate the relationships between eGDR, long-term visit-to-visit HbA1c variability, and adverse outcomes in patients with type 2 diabetes.

This post-hoc analysis of the Action to Control Cardiovascular Risk in Diabetes study (ACCORD) included 10,129 type 2 diabetes patients with high cardiovascular risk. Participants were divided into tertiles based on eGDR values. HbA1c variability was assessed using the HbA1c Variability Score (HVS). Primary outcome was major adverse cardiovascular events (MACEs), composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes. Weibull accelerated failure-time models and causal mediation analyses were employed to evaluate relationships between variables.

During a median follow-up of 4.75 years, compared to T1, T3 showed significantly higher risks of MACEs (HR 1.56, 95% CI: 1.27–1.91) and all-cause mortality (HR 1.81, 95% CI: 1.40–2.32) in fully adjusted models. Restricted cubic spline analysis revealed nonlinear relationships between eGDR and outcomes, with risk declining rapidly as eGDR increased until approximately 5 mg/kg/min, after which the curve flattened. A significant negative correlation was observed between HVS and eGDR (β −2.30; 95% CI: −2.65 to −1.95), following a similar nonlinear pattern. In mediation analysis, HVS explained 37.8% of eGDR’s effect on MACEs risk and 21.53% of its effect on all-cause mortality.

In type 2 diabetes patients with high cardiovascular risk, lower eGDR was associated with higher risk of MACEs and all-cause mortality, with HbA1c variability playing an important mediating role in this relationship.